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PND12
TREATMENT AND HEALTH-CARE 
SATISFACTION AMONG PEOPLE WITH 
MIGRAINE HEADACHES
Mackell JA1, McDonnell DD2
1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 
2Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: Satisfaction with health care has been
linked to positive health-related behavior and improved
efficacy of care. Among people with migraine headaches,
there are unmet needs for appropriate diagnosis, medica-
tions, and care. This analysis will therefore explore
whether treatment of migraines with prescription medi-
cations improves health-care satisfaction.
METHODS: Data were obtained from a spring 2000 sur-
vey. A total of 21,986 (56%) questionnaires were re-
turned from an initial mailing to 39,491 US adults whose
names were purchased from a large marketing company.
The 12-page survey covered a range of health topics in-
cluding opinions, health history, and treatments. Respon-
dents were asked how satisfied they were with their
health care on a six-point scale from “strongly disagree”
(1) to “strongly agree” (6). Migraine status was assessed
by asking whether respondents had migraines (yes/no), if
these were diagnosed by a doctor (yes/no), and if they
used a prescription drug (Rx) to treat them (yes/no). Se-
verity was self-reported as mild, moderate, or severe.
RESULTS: A total of 4,069 people (19%) reported hav-
ing migraines. Of those, 65% (n  2,605) were diag-
nosed and 42% (n  1,090) of those reported currently
using an Rx. Compared to those without migraines, peo-
ple with migraines were less likely to be satisfied with
their health care (59% vs. 51%, p  .001). However,
those treating their migraines with prescription medica-
tion were more likely to be satisfied than those who were
not taking an Rx (59% vs. 50%, p  .001). These bivari-
ate associations remained after controlling for potential
confounders (health-care resource use, overall physical
and mental health), when comparing migraineurs to non-
migraineurs (B  .07, p  0.026) as well as diagnosed
vs. undiagnosed (B  .25, p  .001) and people with at
least moderately severe conditions (B  .26, p  .001).
CONCLUSIONS: People who are successfully treated
have higher health-care satisfaction. Physicians should
therefore work with patients to find a medication that is
effective for their patients’ spectrum of migraine symp-
toms.
PND13
TREATMENT AND QUALITY OF LIFE AMONG 
PEOPLE WITH MIGRAINES
Mackell JA1, McDonnell DD2
1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 
2Consumer Health Sciences, Princeton, NJ, USA
OBJECTIVES: Migraines affect an estimated 11 million
people in the US. Using self-reports, the effects on quality
of life are comparable to, if not worse than, angina, ar-
thritis, or depression. This analysis explores whether
treatment with prescription medication improves mi-
graine sufferers’ quality of life.
METHODS: Data were obtained from a survey conducted
in spring 2000. A total of 21,986 questionnaires were re-
turned (56%) from a mailing to 39,491 US adults whose
names were purchased from a large marketing company.
The 12-pages covered health history, opinions, and treat-
ments. Quality of life was evaluated using the mental score
of the SF-12, a generic measure of health status (Ware, et
al 1996). The mean for US adults is 50; higher scores indi-
cate better well being. Migraine status was assessed by ask-
ing whether respondents had migraines (yes/no), if these
were diagnosed by a doctor (yes/no), and if they used a
prescription drug (Rx) to treat them (yes/no). Severity was
self-reported as mild, moderate, or severe.
RESULTS: A total of 4,069 people (19%) reported mi-
graines. Of these, 65% (n  2,605) were diagnosed and
42% (n  1,090) of these used prescription medications. In
bivariate analyses, those taking an Rx had slightly higher
quality of life than those not taking a drug (46.6 vs. 45.9,
p  .164), even though Rx users had more severe migraines
and severe migraine sufferers tended to have lower quality
of life. Since the relationship between quality of life and Rx
use was confounded by severity, a linear regression model
was run to control for potential confounders (severity, age,
comorbidities, migraine frequency). In this model, those tak-
ing an Rx had higher quality of life than those not taking a
drug (B  1.08, p  0.020).
CONCLUSIONS: Migraine sufferers who are success-
fully treated with prescription medications have higher
quality of life than those not taking medication. Physi-
cians should work with patients to find a medication that
targets their migraine-specific symptoms.
PND14
QUALITY OF LIFE OF WOMEN SUFFERING 
FROM MENSTRUAL MIGRAINE AND 
RELATIONSHIP WITH MOOD
Arpinelli F, Visona G, Roncolato M
Medical Dept. GlaxoSmithKline S.p.A, Verona, Italy
OBJECTIVE: A lot of women suffer from menstrual mi-
graine. This affects quality of life (QoL) and mood. Our sur-
vey: a) evaluated the relationship between menstrual mi-
graine and mood; b) measured the QoL of a sample of
women; c) compared it with the norm for an Italian female.
METHODS: This was a cross-sectional, multicenter survey.
Eligible patients (pts) were those suffering from menstrual
migraine (range: 2 to 3 days around the first day of
menstruation), and receiving an anti-migraine treatment for
4 weeks at least. Doctors reported socio-demographic, clini-
cal and therapeutic data, measured mood of pts by the
Hamilton Depression rating scale (HDRS), and adminis-
tered the SF-36 questionnaire to pts. Demographic and clin-
ical details were summarized by descriptive statistics. HDRS
scores and SF-36 were calculated according to author’s in-
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structions; HDRS total score was correlated to the score in
each SF-36 dimension using Pearson correlation coefficients.
Mean scores of the two categories (depressed, not de-
pressed) were compared with the norm using analysis of co-
variance allowing for effects due to age.
RESULTS: Forty specialists enrolled 663 pts (653 fully
evaluable). Mean age was 35, mean age at diagnosis was
19. Duration of untreated migraine ranged from 4 to 72
hours (82% of pts); migraine was severe in 57.3% of
cases, and throbbing in 78.9%. HDRS scores revealed a
prevalence of depression of 38.9% (HDRS score greater
than 7) among them, although 53.7% suffered from mi-
nor depression. Correlations between HDRS and SF-36
dimensions ranged, in absolute value, from 0.37 to 0.67.
All SF-36 mean scores of depressed pts were significantly
lower than the norm (P  .01). Among not depressed pts,
four out of eight mean scores are significantly lower than
norm (P  0.01).
CONCLUSION: Results of our survey suggest that a
number of women suffering from menstrual migraine are
depressed. A significant role in worsening QoL is played
by depression.
ND15
COST-EFFECTIVENESS OF THERAPY FOR 
RELAPSING-REMITTING MULTIPLE SCLEROSIS 
(RRMS): INTRODUCING AN ECONOMIC MODEL 
FOR COPAXONE (GLATIRAMER ACETATE)
Bose UK
Aventis Pharma UK, West Malling, Kent, UK
MS is the most common neurological disorder among
young adults affecting around 85,000 people in the UK.
Copaxone is a non-interferon disease-modifying agent,
indicated to reduce the frequency of relapses in ambula-
tory patients with active RRMS.
OBJECTIVE: Demonstrate cost-effectiveness based upon
proven economic methodologies.
METHODS: An economic model was developed based
on available data (published efficacy over two and six
years and data on file over eight years) for Copaxone. Di-
rect medical and caregiver costs were taken from the pub-
lished literature. The annual cost of Copaxone is £6,650.
Rather than modeling based upon a hypothetical cohort,
the analysis was developed using patient data from the
trial where possible. The model utilizes the core end-
points of the trial, including number of relapses, disabil-
ity burden via EDSS (Expanded Disability Status Scale) at
each study visit, percentage of patients with improved
EDSS, patients without worsening of EDSS, and without
sustained progression.
RESULTS: Based upon analysis over eight years, cost per
relapse avoided and cost per disability unit avoided were
£11,208 and £9,035 respectively. Dependent on the as-
sumption regarding utility loss during a relapse (two
months with utility loss of 0.083, or six months with a
utility loss of 0.4, and a factor for severity of relapse) the
cost per QALY was between £65,896 and £23,026 re-
spectively. Sensitivity analysis showed these results were
most influenced by changes in the duration of analysis,
utility loss of relapse, and cost of therapy.
CONCLUSIONS: Previous cost-effectiveness analyses for
Copaxone reported in the literature assumed parity price
with the beta-interferons, and did not incorporate new ev-
idence of long-term efficacy. Using this new information,
the reported cost-per-QALY ratio is favourable compared
to accepted standards for cost-effectiveness in the UK.
This analysis provides economic justification for the pre-
scribing of Copaxone to appropriate patients with RRMS.
